A Pandemic Template For Swift Approval? Veklury Stability Questions Deferred For Later Study
Executive Summary
The US FDA shaved months from review of Gilead’s Veklury (remdesivir) for COVID-19 with post-approval commitments for multiple stability studies. The Pink Sheet takes a deep dive look at discussions within the agency and with the sponsor.
You may also be interested in...
Gilead’s Veklury Approval Shows US FDA’s Existing Regulatory Tools Are Up To The COVID-19 Challenge
The FDA emphasized the rigor of its review of the first COVID-19 therapy, which used few expedited pathways on its way to approval after a two-and-a-half-month review. Post-marketing studies will address remaining concerns about dosing and special populations.
Stability Genius: How CMC Section Of COVID-19 Vaccine Guidance Speeds EUAs Safely
By focusing on short-term stability, US FDA paves way for quicker emergency use authorization without compromising on quality.
How Gilead Intends To Deliver On Promise Of Remdesivir For COVID-19
When the coronavirus hit China, Gilead only had enough remdesivir for 5,000 patients. Here’s how it went about expanding production.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: